Literature DB >> 27908751

Enhanced potency of bivalent small molecule gp41 inhibitors.

Vladimir Sofiyev1, Hardeep Kaur1, Beth A Snyder2, Priscilla A Hogan2, Roger G Ptak2, Peter Hwang3, Miriam Gochin4.   

Abstract

Low molecular weight peptidomimetic inhibitors with hydrophobic pocket binding properties and moderate fusion inhibitory activity against HIV-1 gp41-mediated cell fusion were elaborated by increasing the available surface area for interacting with the heptad repeat-1 (HR1) coiled coil on gp41. Two types of modifications were tested: 1) increasing the overall hydrophobicity of the molecules with an extension that could interact in the HR1 groove, and 2) forming symmetrical dimers with two peptidomimetic motifs that could potentially interact simultaneously in two hydrophobic pockets on the HR1 trimer. The latter approach was more successful, yielding 40-60times improved potency against HIV fusion over the monomers. Biophysical characterization, including equilibrium binding studies by fluorescence and kinetic analysis by Surface Plasmon Resonance, revealed that inhibitor potency was better correlated to off-rates than to binding affinity. Binding and kinetic data could be fit to a model of bidentate interaction of dimers with the HR1 trimer as an explanation for the slow off-rate, albeit with minimal cooperativity due to the highly flexible ligand structures. The strong cooperativity observed in fusion inhibitory activity of the dimers implied accentuated potency due to the transient nature of the targeted intermediate. Optimization of monomer, dimer or higher order structures has the potential to lead to highly potent non-peptide fusion inhibitors by targeting multiple hydrophobic pockets.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bivalent inhibitors; Cooperativity; Fluorescence; Fusion inhibition; HIV-1 gp41; Hydrophobic pocket; Kinetics; Peptidomimetic inhibitors; Surface plasmon resonance

Mesh:

Substances:

Year:  2016        PMID: 27908751      PMCID: PMC5260928          DOI: 10.1016/j.bmc.2016.11.010

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  48 in total

Review 1.  Structural basis for membrane fusion by enveloped viruses.

Authors:  W Weissenhorn; A Dessen; L J Calder; S C Harrison; J J Skehel; D C Wiley
Journal:  Mol Membr Biol       Date:  1999 Jan-Mar       Impact factor: 2.857

2.  A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.

Authors:  Lifeng Cai; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

3.  Potent D-peptide inhibitors of HIV-1 entry.

Authors:  Brett D Welch; Andrew P VanDemark; Annie Heroux; Christopher P Hill; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

4.  Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.

Authors:  Shinya Oishi; Saori Ito; Hiroki Nishikawa; Kentaro Watanabe; Michinori Tanaka; Hiroaki Ohno; Kazuki Izumi; Yasuko Sakagami; Eiichi Kodama; Masao Matsuoka; Nobutaka Fujii
Journal:  J Med Chem       Date:  2008-01-16       Impact factor: 7.446

5.  Increase of anti-HIV activity of C-peptide fusion inhibitors using a bivalent drug design approach.

Authors:  Yanbo Ling; Huifang Xue; Xifeng Jiang; Lifeng Cai; Keliang Liu
Journal:  Bioorg Med Chem Lett       Date:  2013-07-16       Impact factor: 2.823

6.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

7.  Conformer generation with OMEGA: learning from the data set and the analysis of failures.

Authors:  Paul C D Hawkins; Anthony Nicholls
Journal:  J Chem Inf Model       Date:  2012-11-12       Impact factor: 4.956

Review 8.  Molecular determinants of drug-receptor binding kinetics.

Authors:  Albert C Pan; David W Borhani; Ron O Dror; David E Shaw
Journal:  Drug Discov Today       Date:  2013-02-27       Impact factor: 7.851

Review 9.  Peptides in the treatment of AIDS.

Authors:  Fred Naider; Jacob Anglister
Journal:  Curr Opin Struct Biol       Date:  2009-07-23       Impact factor: 6.809

10.  Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Authors:  Kristen M Kahle; H Kirby Steger; Michael J Root
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more
  3 in total

1.  Evaluation of ligand-based NMR screening methods to characterize small molecule binding to HIV-1 glycoprotein-41.

Authors:  Shidong Chu; Guangyan Zhou; Miriam Gochin
Journal:  Org Biomol Chem       Date:  2017-06-07       Impact factor: 3.876

2.  Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis.

Authors:  Heng Zhang; Bo Zhou; Su Qin; Jing Xu; Rachel Harding; Wolfram Tempel; Vinod Nayak; Yanjun Li; Peter Loppnau; Yali Dou; Jinrong Min
Journal:  Genes Dev       Date:  2018-03-21       Impact factor: 11.361

3.  Conformational Stabilization of Gp41-Mimetic Miniproteins Opens Up New Ways of Inhibiting HIV-1 Fusion.

Authors:  Mario Cano-Muñoz; Julie Lucas; Li-Yun Lin; Samuele Cesaro; Christiane Moog; Francisco Conejero-Lara
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.